It had been suggested that low-dose aspirin might protect against cancer, but we saw no reduction in any cancers we are continuing to follow the participants to see whether any benefits appear later." Professor Jane Armitage, principal investigator, Nuffield Department of Population Health, University of Oxford, UK, said: "Even though we showed clearly that aspirin reduces the risk of vascular events, including heart attacks, strokes, and mini-strokes, it also increased the risk of major bleeds, mainly from the gastrointestinal tract, so overall there was no clear benefit. Researchers noted it was not possible to identify a group of patients in whom the benefits of aspirin use clearly outweighed the risks. These findings were consistent even among participants at the highest cardiovascular risks. However, a first major bleed occurred in 314 of those in the aspirin group (4.1 percent) compared with 245 of those in the placebo group (3.2 percent) meaning nine of every 1,000 participants suffered a first major bleed during the trial due to aspirin. According to researchers, this translated to 11 of every 1,000 participants avoiding a serious vascular event during the trial as a result of aspirin, as well as a 12 percent proportional reduction in the risk of serious vascular events. Overall findings showed a first serious vascular event occurred in 685 participants (8.5 percent) in the aspirin group compared with 743 in the placebo group (9.6 percent). During an average 7.4 years of follow up, they assessed the primary efficacy endpoint of first serious vascular event (non-fatal heart attack, non-fatal stroke, or death from cardiovascular cause) as well as the primary safety endpoint of first major bleed serious enough to require hospitalization or be fatal. In the ASCEND aspirin study, simultaneously published in the New England Journal of Medicine (NEJM), researchers randomly assigned 15,480 patients with diabetes but no history of cardiovascular disease to aspirin (100 mg daily) or placebo. 26 found fish oil supplements did not reduce the risk of cardiovascular events or stroke in this patient group. Additionally, a separate ASCEND study also presented Aug. 26 from the ASCEND trial as part of ESC Congress 2018. When combined, the results of the two trials show clear and consistent evidence that aspirin prevents recurrent blood clots and this is likely to be adopted into future international practice.The benefits of aspirin use in preventing serious vascular events in diabetic patients were largely counterbalanced by major bleeding events, said investigators presenting findings on Aug. The study results are consistent with the findings of an Italian study, called WARFASA, which a showed a significant benefit with aspirin as reported in The New England Journal of Medicine earlier this year. We now have clear evidence that aspirin is of benefit for patients who are unable or do not wish to continue warfarin in the long term." "Aspirin reduces the risk of important blood clotting event including recurrent VTE, myocardial infarction, stroke, or cardiovascular death. "Many patients discontinue warfarin therapy after six or twelve months of treatment due to the inconvenience of regular blood tests and the increased risks of serious bleeding. On average participants were followed for three years.ĭr Tim Brighton, from Prince of Wales Hospital and principal investigator of the study, explained: They were randomly allocated to receive either low dose enteric coated aspirin or a matching placebo. They had completed on average six months of anti-coagulant treatment, generally with warfarin. All the participants had previously suffered a DVT or PE that occurred for no particular reason, called 'unprovoked VTE' (venous thromboembolism). Operating since 2003, the ASPIRE study completed recruitment of 822 participants from five countries including Australia, New Zealand, Singapore, India and Argentina. For every 1000 patients treated for one year, aspirin can be expected to prevent about 20 to 30 episodes of recurrent major thrombotic events at the cost of about three significant bleeding episodes." "These results suggest that aspirin prevents about one third of recurrent blood clot events. The results suggests low-dose aspirin prevented about one third of recurrent blood clot events.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |